Physician

Coral Oghenerukevwe Omene, M.D., PH.D

According to 2025 Medicare claims, Coral Omene, M.D., PH.D (NPI: 1861688988) practices medical oncology in the Lakewood-New Brunswick, NJ market, with the plurality of this provider's patient population coming from Middlesex, NJ. This provider's primary affiliated billing organization is RUTGERS HEALTH-RWJ SCLERODERMA PROGRAM (NPI: 1518904929; TIN: 223371727) and primary practice location at 08901-1992. Omene is affiliated with the Vytalize Health 9 ACO LLC (ACO ID: D0313), participating under the REACH model.

Omene's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 115 traditional Medicare patients, billed 215 HCPCS/CPT codes, and received $21,401 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 316 prescription claims across 99 beneficiaries totaling $847,119 in drug costs, led by Ibrance (Palbociclib). 2023 DME data shows 38 claims. Open Payments data shows 12 records totaling $239,418. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $15,152 to $847,119. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	34	85	$10,171
2018	82	294	$36,310
2019	80	265	$34,568
2020	92	248	$29,464
2021	86	220	$27,786
2022	94	252	$30,250
2023	96	163	$16,816
2024	115	215	$21,401

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	15	160	$15,152
2016	14	119	$8,633
2017	16	76	$6,880
2018	28	123	$2,012
2019	55	294	$233,798
2020	61	249	$304,841
2021	43	136	$307,458
2022	79	250	$248,410
2023	93	270	$436,723
2024	99	316	$847,119

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	46	$3,793
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	38	$1,881
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	22	22	$154
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	67	126	$109
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	18	18	$63
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	22	26	$14

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	21	606	$337,901
Verzenio	Abemaciclib	21	588	$312,984
Letrozole	Letrozole	111	8,414	$3,083
Exemestane	Exemestane	14	1,080	$1,856
Tamoxifen Citrate	Tamoxifen Citrate	40	3,064	$551

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$2,740	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	11	$236,678	Regeneron Pharmaceuticals, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Coral Oghenerukevwe Omene, M.D., PH.D?

Tedicare shows public-source Medicare data for Coral Oghenerukevwe Omene, M.D., PH.D (NPI 1861688988), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Coral Oghenerukevwe Omene, M.D., PH.D have ACO affiliation data?

Coral Oghenerukevwe Omene, M.D., PH.D is shown with ACO affiliation data for Vytalize Health 9 ACO LLC (REACH, ACO ID D0313).

What billing organization is linked to Coral Oghenerukevwe Omene, M.D., PH.D?

Coral Oghenerukevwe Omene, M.D., PH.D is linked to RUTGERS HEALTH-RWJ SCLERODERMA PROGRAM (billing NPI 1518904929) in the available physician profile data.

Does Coral Oghenerukevwe Omene, M.D., PH.D have Open Payments data?

Coral Oghenerukevwe Omene, M.D., PH.D has 12 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.